CytoDyn Selects Waisman Facility to Manufacture Its DNA-Based Pre-Flu Vaccine

SANTA FE, N.M.--(BUSINESS WIRE)--CytoDyn, Inc. (Pink Sheets:CYDY) has selected the Waisman Clinical BioManufacturing Facility at the University of Wisconsin at Madison to manufacture the Company’s DNA-based pre-flu vaccine. CytoDyn’s pre-flu vaccine provides an alternative approach to immunization that could make flu vaccines for the seasonal flu and bird flu more effective. It uses DNA technology to implant a false memory of previous exposure to the flu virus, including the inactivated virus contained in standard vaccines.

Back to news